Lucas T. Moreno

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 134 publications

Establishing a Multicenter Personalized Medicine Program in Childhood, Adolescent, and Young Adult Cancer in Spain: The SEHOP-PENCIL Project.

Establishing a Multicenter Personalized Medicine Program in Childhood, Adolescent, and Young Adult Cancer in Spain: The SEHOP-PENCIL Project.

Journal: JCO precision oncology

Published: September 01, 2026

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Association Between Dinutuximab Beta Exposure and Post-End-of-Treatment Survival in Neuroblastoma: A Weighted Patient-Level Analysis of Three Clinical Studies.

Journal: Pediatric blood & cancer

Published: May 10, 2026

Development of an age specific EORTC questionnaire to assess the health-related quality of life (HRQOL) of children with cancer aged 8-14 years - a mixed-methods content elicitation phase I & II EORTC QLG study.

Development of an age specific EORTC questionnaire to assess the health-related quality of life (HRQOL) of children with cancer aged 8-14 years - a mixed-methods content elicitation phase I & II EORTC QLG study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 05, 2026

Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma.

Impact of Metastatic Patterns on Survival and Response to Therapy in Neuroblastoma.

Journal: Pediatric blood & cancer

Published: May 04, 2026

Reply to: Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno.

Reply to: Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 30, 2026

Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium.

Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 23, 2026

Assessing the Validity and Acceptability of an Adult Quality of Life Questionnaire, the EORTC QLQ-C30, for Adolescents With Cancer.

Assessing the Validity and Acceptability of an Adult Quality of Life Questionnaire, the EORTC QLQ-C30, for Adolescents With Cancer.

Journal: Cancer medicine

Published: February 26, 2026

Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.

Dabrafenib in pediatric patients with BRAF V600 mutation-positive high-grade glioma: Results from a phase 1/2a single-arm study.

Journal: Neuro-oncology practice

Published: December 29, 2025

Response to the letter to the editor entitled "The precision of a report on precision".

Response to the letter to the editor entitled "The precision of a report on precision".

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: December 25, 2025

Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity.

Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity.

Journal: NPJ precision oncology

Published: December 18, 2025

Current treatment strategies for first relapse of high-risk neuroblastoma.

Current treatment strategies for first relapse of high-risk neuroblastoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 16, 2025

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2025

Showing 1-12 of 134

Last Updated: 09/26/2026